MetaCap

EDAP TMS S.A. ADR (FOCL)

NASDAQ: FOCLHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD

2.61-0.21 (-7.45%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

FOCL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$123.25M
EPS (TTM)
-$1.35
52-week range
2.11 – 6.40
Day range
2.55 – 3.10
Volume / Avg
143.15K / 137.30K
Beta
—

52-week range

$2.11$6.40

FOCL stock today

Shares of EDAP TMS S.A. (FOCL) finished lower on Nov 20 at $2.61, a drop of 7.45% or $0.21 per share, versus the S&P 500's 3.70% decline. At this level, FOCL sits near the bottom of its 52-week range of $2.11 to $6.40: 59.2% below the high, set on Aug 4, 2026 and 23.7% above the low. FOCL is down 20.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 13.5%.

EDAP TMS S.A. has posted a net loss over the last twelve months (EPS of -$1.35), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About EDAP TMS S.A.

Company profile

EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services.

Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
CEO
Mr. Ryan Rhodes
Headquarters
Vaulx-En-Velin
Employees
289

Financial highlights

Full financials

In fiscal 2025, EDAP TMS S.A. generated $70.5 million in revenue, up 1.6% from fiscal 2024. EDAP TMS S.A. reported a net loss of $29.2 million, compared with a loss of $20.6 million a year earlier. Gross margin was 42.5% (up from 41.4%) and operating margin -35.0%.

EDAP TMS S.A. annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024
Revenue$70.53M$69.39M
Growth+1.63%—
Net income$-29.25M$-20.58M
EPS (diluted)$-0.78$-0.55

Analyst forecast

Forecast

Consensus (5 analysts)

buy

Avg. price target

$8.30+218.01%

  • Strong buy 0
  • Buy 3
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $15.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.10 vs $-0.18
Surprise
+44.44%

FOCL news

All FOCL news

EDAP TMS S.A. peers

Health Care sector
FOCL peer companies
CompanyPrice% ChgMarket capCompare
VANIVivani Medical Inc.1.14+4.59%$102.83Mvs FOCL
STXSStereotaxis Inc.0.9422-6.71%$95.03Mvs FOCL
HSDTSolana Company Class A1.49-10.24%$93.70Mvs FOCL
NRXSNeuraxis Inc.4.22-6.22%$59.90Mvs FOCL
ELMDElectromed Inc.22.98-1.20%$187.84Mvs FOCL
HYPRHyperfine Inc. Class A0.5465+4.27%$57.96Mvs FOCL
OMOutset Medical Inc.2.81-3.44%$53.03Mvs FOCL
POCIPrecision Optics Corporation Inc.4.12+1.41%$45.30Mvs FOCL

Indexes, lists and sector

EDAP TMS S.A. stock FAQ

What is EDAP TMS S.A.'s stock price today?

FOCL last traded at $2.61 as of Nov 20, 4:00 PM EST, down 7.45% on the day. Prices are delayed at least 15 minutes.

Who is EDAP TMS S.A.'s CEO?

Mr. Ryan Rhodes is the chief executive officer of EDAP TMS S.A. ADR, which has about 289 employees.

What is the FOCL 52-week high?

The 52-week high for FOCL is $6.40 and the 52-week low is $2.11. The stock is currently 59.2% below its high.

Compare FOCL